Dark

DSGN
Design Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open

Aug 7, 2026 1:27:31 PM EDT

13.77USD-0.036%(-0.01)106,472

13.74Bid 13.81Ask 0.07Spread

Pre-market

Aug 6, 2026 9:21:30 AM EDT

13.60USD+0.221%(+0.03)0

After-hours

Aug 6, 2026 4:06:30 PM EDT

14.04USD+1.850%(+0.26)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 19, 2022

05:41AM EST Goldman Sachs Initiates Coverage On Design Therapeutics with Sell Rating, Announces Price Target of $10 Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 8, 2021

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

06:42AM EDT Design Therapeutics Announces Positive Preclinical Data From Novel DM1 GeneTAC Program RTTNews

06:31AM EDT Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1 Benzinga

06:30AM EDT Design Therapeutics Announces Positive Preclinical Data GlobeNewswire Inc

Aug 9, 2021

04:05PM EDT Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 GlobeNewswire Inc

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jun 7, 2021

04:10PM EDT Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that Joo Siffert, M.D., president and chief executive officer, will participate in a fireside chat during the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 1:20 p.m. ET. GlobeNewswire Inc

04:05PM EDT Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appointments of industry veterans, Heather Behanna, Ph.D., principal of SR One, and Deepa Prasad, managing director of WestRiver Group, to its board of directors effective June 15, 2021. GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 10, 2021

04:28PM EDT Design Therapeutics Q1 EPS $(0.31) Down From $(0.04) YoY Benzinga

04:05PM EDT Successful $276 Million IPO Completed to Advance GeneTACTM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development GlobeNewswire Inc

Apr 23, 2021

07:28AM EDT The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs Benzinga

Apr 22, 2021

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 20, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021 Benzinga

07:51AM EDT SVB Leerink Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $36 Benzinga

06:52AM EDT Goldman Sachs Initiates Coverage On Design Therapeutics with Neutral Rating, Announces Price Target of $28 Benzinga

06:50AM EDT Piper Sandler Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $42 Benzinga

Apr 15, 2021

07:49AM EDT The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Mar 30, 2021

04:05PM EDT Design Therapeutics Announces Closing of Initial Public Offering GlobeNewswire Inc

Mar 26, 2021

12:44PM EDT Design Therapeutics Shares Open For Trade At $28; IPO Priced At $20/Share Benzinga

09:17AM EDT Design Therapeutics Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $20/Share Benzinga

12:22AM EDT Design Therapeutics Prices IPO Of 12 Mln Shares At $20/Shr RTTNews

Mar 25, 2021

11:56PM EDT Design Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire Inc

.dark-mode .hK50vC{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .hK50vC{ color: #333333; background-color: white; border: 2px solid #333333; }DSGNDesign Therapeutics, Inc. Common Stockstock NASDAQ

DSGN
Design Therapeutics, Inc. Common Stock
stock NASDAQ